Evolution of raltegravir resistance during therapy

Objectives We investigated the prevalence of raltegravir resistance-associated mutations at baseline and their evolution during raltegravir therapy in patients infected with different HIV-1 subtypes. Methods At pre-treatment screening, the integrase gene from plasma samples from patients infected wi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of antimicrobial chemotherapy 2009-07, Vol.64 (1), p.25-32
Hauptverfasser:	Sichtig, Nadine, Sierra, Saleta, Kaiser, Rolf, Däumer, Martin, Reuter, Stefan, Schülter, Eugen, Altmann, Andre, Fätkenheuer, Gerd, Dittmer, Ulf, Pfister, Herbert, Esser, Stefan
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Substitution - genetics Antibiotics. Antiinfectious agents. Antiparasitic agents Antiretroviral drugs antiviral therapy Biological and medical sciences DNA Mutational Analysis Drug resistance Drug Resistance, Viral Genotype & phenotype HIV HIV Infections - drug therapy HIV Infections - virology HIV Integrase - genetics HIV-1 HIV-1 - drug effects HIV-1 - genetics HIV-1 - isolation & purification Human immunodeficiency virus Human immunodeficiency virus 1 Human viral diseases Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Infectious diseases integrase inhibitors Medical sciences Molecular Sequence Data Mutation Mutation, Missense non-B subtypes Pharmacology. Drug treatments Pyrrolidinones - pharmacology Pyrrolidinones - therapeutic use Raltegravir Potassium Sequence Analysis, DNA Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objectives We investigated the prevalence of raltegravir resistance-associated mutations at baseline and their evolution during raltegravir therapy in patients infected with different HIV-1 subtypes. Methods At pre-treatment screening, the integrase gene from plasma samples from patients infected with subtype B and non-B viruses was analysed. Raltegravir resistance evolution was further evaluated in 10 heavily pre-treated patients. Results Two hundred and nine plasma samples from 94 subtype B and 115 non-B patients were sequenced. No signature/primary raltegravir resistance mutations were detected at baseline. The secondary mutations L74M, T97A, V151I and G163R were observed with a frequency of
ISSN:	0305-7453 1460-2091
DOI:	10.1093/jac/dkp153